Pressure BioSciences Inc. (PBIO)
Stock Price Chart
Key Info
| Market Cap | 5.83M |
| Revenue (ttm) | 1.34M |
| Net Income (ttm) | -16.91M |
| Shares Out | 3.88M |
| EPS (ttm) | -5.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | November 24 |
| Last Price | $1.50 |
| Previous Close | $1.53 |
| Change ($) | -0.03 |
| Change (%) | -1.96% |
| Day's Open | 1.30 |
| Day's Range | 1.30 - 1.60 |
| Day's Volume | 10,321 |
| 52-Week Range | 0.6006 - 4.49 |
More Stats
| Market Cap | 5.83M |
| Enterprise Value | 13.57M |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 3.88M |
| Float | n/a |
| EPS (basic) | -6.03 |
| EPS (diluted) | -5.90 |
| FCF / Share | -1.44 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 6,336 |
| Short Ratio | 3.00 |
| Short % of Float | n/a |
| Beta | 1.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 4.36 |
| PB Ratio | n/a |
| Revenue | 1.34M |
| Operating Income | -5.48M |
| Net Income | -16.91M |
| Free Cash Flow | -5.21M |
| Net Cash | -7.74M |
| Net Cash / Share | -1.99 |
| Gross Margin | -40.75% |
| Operating Margin | -410.52% |
| Profit Margin | -1,266.30% |
| FCF Margin | -390.11% |
| ROA | -127.69% |
| ROE | n/a |
| ROIC | 158.70% |
Analyst Forecasts
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.81 | 2.46 | 2.24 | 1.98 | 1.80 | 1.37 | 1.50 | 1.24 | 0.99 | 1.34 |
| Revenue Growth | -26.36% | 9.7% | 13.36% | 9.95% | 30.77% | -8.55% | 21.41% | 25.36% | -26.29% | - |
| Gross Profit | 0.61 | 1.18 | 0.97 | 1.14 | 1.19 | 0.72 | 0.94 | 0.82 | 0.64 | 0.96 |
| Operating Income | -5.81 | -4.48 | -4.65 | -3.74 | -3.57 | -3.34 | -3.33 | -3.46 | -3.29 | -3.40 |
| Net Income | -11.66 | -9.70 | -10.72 | -2.71 | -7.42 | -4.61 | -4.08 | -3.45 | -3.00 | -3.13 |
| Shares Outstanding | 1.99 | 1.53 | 1.11 | 0.91 | 0.69 | 0.48 | 0.39 | 0.34 | 0.22 | 0.09 |
| Earnings Per Share | -7.98 | -15.33 | -9.62 | -2.97 | -10.77 | -13.20 | -13.20 | -12.90 | -23.10 | -40.50 |
| Operating Cash Flow | -6.33 | -5.70 | -3.90 | -3.81 | -3.82 | -3.21 | -2.34 | -2.16 | -2.14 | -2.87 |
| Capital Expenditures | -0.02 | - | -0.02 | -0.01 | -0.01 | -0.01 | -0.06 | - | - | -0.09 |
| Free Cash Flow | -6.35 | -5.70 | -3.93 | -3.81 | -3.83 | -3.22 | -2.40 | -2.16 | -2.14 | -2.96 |
| Cash & Equivalents | 0.03 | 0.10 | 0.08 | 0.14 | 0.12 | 0.47 | 0.03 | 0.01 | 0.23 | 0.58 |
| Total Debt | 7.96 | 5.00 | 13.17 | 5.51 | 0.43 | 1.08 | 0.47 | 1.04 | 0.54 | - |
| Net Cash / Debt | -7.93 | -4.90 | -13.09 | -5.37 | -0.31 | -0.61 | -0.44 | -1.03 | -0.32 | 0.58 |
| Assets | 1.82 | 2.40 | 2.16 | 1.63 | 1.80 | 1.74 | 1.10 | 1.35 | 1.94 | 2.59 |
| Liabilities | 13.87 | 8.52 | 16.78 | 10.01 | 9.78 | 3.80 | 3.07 | 2.89 | 2.35 | 0.78 |
| Book Value | -12.06 | -6.13 | -14.62 | -8.38 | -7.98 | -2.06 | -1.97 | -1.54 | -0.41 | 1.81 |
Company Profile
Company Details
| Full Name | Pressure BioSciences Inc. |
| Country | United States |
| Employees | 14 |
| CEO | Richard T. Schumacher |
Stock Information
| Ticker Symbol | PBIO |
| Stock Exchange | US OTC |
| Sector | Healthcare |
| Industry | Medical Devices |
| Unique Identifier | OTCMKTS: PBIO |
| IPO Date | October 31, 1996 |
Description
Pressure BioSciences develops pressure cycling technology (PCT) solutions in North America, Europe, and Asia. Its PCT technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations, including Barocycler 2320EXT, Barozyme-HT48, Barocycler HUB440, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as pressure used to lyse samples for extraction tubes and other processing tubes, as well as application specific kits, including consumable products and reagents. It serves government institutions, pharmaceutical and biotechnology companies, and academic laboratories. Pressure BioSciences, Inc. has a collaboration with The Steinbeis Centre for biopolymer analysis and biomedical mass spectrometry; and NutraLife Biosciences for the development of water-soluble Nanoemulsion-based nutraceuticals. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was founded in 1978 and is based in South Easton, Massachusetts.